AstraZeneca: EMA continues investigations
(CercleFinance.com) - The Safety and Pharmacovigilance Committee (PRAC) of the EMA (European Medicines Agency) is meeting this Wednesday as part of the ongoing investigation into the very rare cases of blood clots associated with low platelet counts in some people vaccinated with Vaxzevria, the name of AstraZeneca's Covid-19 vaccine.
The EMA convened a meeting of an ad hoc expert group (independent external experts, hematologists, neurologists, epidemiologists etc.) on Monday 29 March to provide additional input to the ongoing evaluation, with the aim of identifying possible underlying risk factors.
The outcome of this meeting will be discussed by the PRAC and will add to its ongoing assessment.
At present, the EMA recalls that no specific risk factors, such as age, gender, or a medical history of bleeding disorders, have been identified. Furthermore, a causal link with the vaccine has not been proven, but it remains possible and further analysis is ongoing.
The share is down about 0.5% on Wednesday afternoon.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The EMA convened a meeting of an ad hoc expert group (independent external experts, hematologists, neurologists, epidemiologists etc.) on Monday 29 March to provide additional input to the ongoing evaluation, with the aim of identifying possible underlying risk factors.
The outcome of this meeting will be discussed by the PRAC and will add to its ongoing assessment.
At present, the EMA recalls that no specific risk factors, such as age, gender, or a medical history of bleeding disorders, have been identified. Furthermore, a causal link with the vaccine has not been proven, but it remains possible and further analysis is ongoing.
The share is down about 0.5% on Wednesday afternoon.
Copyright (c) 2021 CercleFinance.com. All rights reserved.